Abstract
Gastric cancer is among the leading causes of cancer related death worldwide. Patients with gastric cancer are typically asymptomatic, and diagnosed at late stages, supporting the need for the identification of novel prognostic and diagnostic biomarkers. Recently, microRNAs have emerged as molecular regulators that can play key roles in pathogenesis and progression of different malignancies, including gastric cancer. There is a growing body of evidence showing the aberrant activation of some known circulating miRNAs, e.g. let-7a, miR-21, miR-16, miR-93, miR- 103, miR-192a s well as tissue specific-miRNAs, e.g. miR-18a, miR-10b, miR-544, miR-195, miR-378, miR-34a, miR-145 in patients affected by gastric cancer, which involved with modulation of gastric-cancer-associated genes. In addition, there are mounting evidences on the value of miRNAs which are detected to be associated with drug-resistance mechanisms; suggesting their modulation as a potential approach to overcome chemo-resistance. Attuned with these facts, in this review we highlight several recent preclinical and clinical studies performed on circulating and tissue-specific miRNAs as promising biomarkers for detection of patients at early stages, prediction of prognosis, and monitoring of the patients in response to therapy.
Keywords: Gastric cancer, MiRNA, circulating biomarker, tissue-specific biomarker.
Current Medicinal Chemistry
Title:Circulating microRNAs as Potential Diagnostic Biomarkers and Therapeutic Targets in Gastric Cancer: Current Status and Future Perspectives
Volume: 23 Issue: 36
Author(s): Hamed Mirzaei, Sara Khataminfar, Saeid Mohammadparast, Soudabeh Shahid Sales, Mina Maftouh, Mohsen Mohammadi, Miganoosh Simonian, Seyed Mohammd Reza Parizadeh, Seyed Mahdi Hassanian and Amir Avan
Affiliation:
Keywords: Gastric cancer, MiRNA, circulating biomarker, tissue-specific biomarker.
Abstract: Gastric cancer is among the leading causes of cancer related death worldwide. Patients with gastric cancer are typically asymptomatic, and diagnosed at late stages, supporting the need for the identification of novel prognostic and diagnostic biomarkers. Recently, microRNAs have emerged as molecular regulators that can play key roles in pathogenesis and progression of different malignancies, including gastric cancer. There is a growing body of evidence showing the aberrant activation of some known circulating miRNAs, e.g. let-7a, miR-21, miR-16, miR-93, miR- 103, miR-192a s well as tissue specific-miRNAs, e.g. miR-18a, miR-10b, miR-544, miR-195, miR-378, miR-34a, miR-145 in patients affected by gastric cancer, which involved with modulation of gastric-cancer-associated genes. In addition, there are mounting evidences on the value of miRNAs which are detected to be associated with drug-resistance mechanisms; suggesting their modulation as a potential approach to overcome chemo-resistance. Attuned with these facts, in this review we highlight several recent preclinical and clinical studies performed on circulating and tissue-specific miRNAs as promising biomarkers for detection of patients at early stages, prediction of prognosis, and monitoring of the patients in response to therapy.
Export Options
About this article
Cite this article as:
Mirzaei Hamed, Khataminfar Sara, Mohammadparast Saeid, Sales Shahid Soudabeh, Maftouh Mina, Mohammadi Mohsen, Simonian Miganoosh, Parizadeh Mohammd Reza Seyed, Hassanian Mahdi Seyed and Avan Amir, Circulating microRNAs as Potential Diagnostic Biomarkers and Therapeutic Targets in Gastric Cancer: Current Status and Future Perspectives, Current Medicinal Chemistry 2016; 23 (36) . https://dx.doi.org/10.2174/0929867323666160818093854
DOI https://dx.doi.org/10.2174/0929867323666160818093854 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Innovations and Improvements in Pharmacokinetic Models Based on Physiology
Current Drug Delivery The Stomach as an Energy Homeostasis Regulating Center. An Approach for Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cdc42 Signaling Pathway Inhibition as a Therapeutic Target in Ras- Related Cancers
Current Medicinal Chemistry Apoptotic Signaling in Pancreatic Cancer – Therapeutic Application (Supplemental Data)
Current Cancer Therapy Reviews Immune Modulation by Ionizing Radiation and its Implications for Cancer Immunotherapy
Current Pharmaceutical Design Targeting the Endocannabinoid System for the Treatment of Cancer – A Practical View
Current Topics in Medicinal Chemistry Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology Developments in Synthesis of the Anti-inflammatory Drug, Celecoxib: A Review
Recent Patents on Inflammation & Allergy Drug Discovery Angiogenesis as a therapeutic target in breast cancer
Mini-Reviews in Medicinal Chemistry Obesity-Driven Inflammation and Colorectal Cancer
Current Medicinal Chemistry The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?
Current Drug Targets Histone Deacetylases as Targets for Dietary Cancer Preventive Agents: Lessons Learned with Butyrate, Diallyl Disulfide, and Sulforaphane
Current Drug Targets miR-1271 Regulates Cisplatin Resistance of Human Gastric Cancer Cell Lines by Targeting IGF1R, IRS1, mTOR, and BCL2
Anti-Cancer Agents in Medicinal Chemistry microRNAs in Cancer: Lessons from Melanoma
Current Pharmaceutical Design Magnetic Resonance Contrast Media Sensing In Vivo Molecular Imaging Agents: An Overview
Current Radiopharmaceuticals Exosomal microRNAs as Potentially Useful Tools in Cancer Biomarker Discovery
Recent Patents on Biomarkers Signal Transduction Therapy with Rationally Designed Kinase Inhibitors
Current Signal Transduction Therapy The Applicability of mTOR Inhibition in Solid Tumors
Current Cancer Drug Targets Paclitaxel Nanoparticles Induce Apoptosis and Regulate TXR1, CYP3A4 and CYP2C8 in Breast Cancer and Hepatoma Cells
Anti-Cancer Agents in Medicinal Chemistry Synthetic Optimization of Ellipticine and Antitumor Activity of Novel Hexacyclic Derivatives of Ellipticine
Current Pharmaceutical Design